Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition
share announcement

Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (30 October 2024) | Viewed by 4906

Special Issue Editors

Prof. Dr. Laurent Kodjikian

E-Mail Website
Guest Editor
Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon 1, 69004 Lyon, France
Interests: retina; DME; AMD; uveitis; steroids; anti-VEGF
Special Issues, Collections and Topics in MDPI journals
Dr. Thibaud Mathis

E-Mail Website
Guest Editor
Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon 1, 69004 Lyon, France
Interests: retina; DME; AMD; oncology; steroids; anti-VEGF
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes is an epidemic disease with a prevalence that will double over the next 20 years. Diabetic macular oedema is the main cause of visual impairment in young people under 50. Screening for diabetic retinopathy is essential and is increasingly assisted by artificial intelligence. The classification of diabetic retinopathy is now quite old and must evolve, particularly with the help of OCT. Diagnosis has become multimodal. Numerous treatments exist, from anti-VEGF to steroids, with short- or long-acting molecules. The handling of these products is improving, and experience with them is growing. The results of observational studies sometimes differ a little or a lot from randomized controlled studies. Observational real-life studies are therefore becoming increasingly important in the medical world because they are relevant to our daily clinical practice. New treatments are also being considered.

Therefore, I wanted a Special Issue in Pharmaceutics to be quite open about the ophthalmological damage of diabetes, from diabetic retinopathy to diabetic macular oedema, more specifically dedicated to its therapeutic management. Indeed, I would like to receive original articles about new molecules with new drug molecular structures, new pathways of action, new mechanisms of action, new combination therapies or even biosimilars. Articles on short, medium or long delivery systems, such as implants, are welcome, especially on steroids, which are classical in DME management.

Prof. Dr. Laurent Kodjikian
Dr. Thibaud Mathis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • diabetic macular edema (DME)
  • diabetic
  • retinopathy
  • anti-VEGF to steroids
  • molecular structures
  • drug development
  • drug targeting
  • combination therapies
  • delivery system
  • implants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2941 KiB  
Article
Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment
by Qing Wen, Helene Karcher, David M. Wright, Samriddhi Buxy Sinha, Usha Chakravarthy, Catarina Santos, Franklin Igwe, Recivall Salongcay, Katie Curran and Tunde Peto
Pharmaceutics 2025, 17(1), 99; https://doi.org/10.3390/pharmaceutics17010099 - 13 Jan 2025
Viewed by 794
Abstract
Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records [...] Read more.
Background/Objectives: The visual acuity (VA) outcomes after the first and second years of anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular oedema (DMO) were evaluated, and the factors associated with treatment success were investigated. Methods: Using Medisoft electronic medical records (UK), this retrospective cohort study analysed VA outcomes, changes, and determinants in DMO patients at year 1 and year 2 after initial anti-VEGF injection. Descriptive analysis examined baseline demographics and clinical characteristics, while regression models were used to assess associations between these factors and changes in VA. Results: 728 DMO patients (1035 eyes) treated with anti-VEGFs (ranibizumab, aflibercept, or bevacizumab) at the Northern Ireland Mater Macular Clinic from 2008 to 2021 were evaluated. The mean age was 64.5 (SD 12.8) years, and 59.6% were male. In the first year, the median annual injection number and interval were 6.0 (IQR 5.0–8.0) and 6.1 weeks (IQR 5.4–7.8), respectively, and in the second year, they were 3.0 (IQR 2.0–5.0) and 10.0 weeks (IQR 6.5–20.1). In the first two treatment years, 83.4% and 79.8% of eyes had improved/stable VA (ISVA) respectively. The injection number, interval, baseline VA, age, and proliferative diabetic retinopathy (PDR) significantly impacted VA outcomes. Conclusions: Our study confirms the effectiveness of anti-VEGF treatments in improving or maintaining vision for DMO patients, consistent with previous real-world clinical data. An elder age, a better baseline VA, low annual injection numbers (<5), and less frequent injection intervals (≥12 weeks) were negatively associated with ISVA success in the first two years. These findings have implications for managing patient expectations, allocating resources, and understanding DMO clinical management. Full article
(This article belongs to the Special Issue Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 506 KiB  
Review
The Effects of Slow-Release Dexamethasone in the Treatment of Diabetic Macular Edema
by Enzo Maria Vingolo, Simona Mascolo, Lorenzo Casillo and Mattia Calabro
Pharmaceutics 2025, 17(2), 174; https://doi.org/10.3390/pharmaceutics17020174 - 30 Jan 2025
Viewed by 734
Abstract
Objectives: to evaluate the efficacy of 0.7 mg dexamethasone intravitreal implant in the treatment of patients with diabetic macular edema through mean retinal sensitivity (MRS), best corrected visual acuity (BCVA), central retinal thickness (CRT) and fixation stability. Methods: patients (n = 50) with [...] Read more.
Objectives: to evaluate the efficacy of 0.7 mg dexamethasone intravitreal implant in the treatment of patients with diabetic macular edema through mean retinal sensitivity (MRS), best corrected visual acuity (BCVA), central retinal thickness (CRT) and fixation stability. Methods: patients (n = 50) with DME, best corrected visual acuity (BCVA) of 0.1 logMAR, and central retinal thickness (CRT) of ≥300 μm determined by optical coherence tomography were treated with 0.7 mg slow-release dexamethasone, and endpoints were evaluated one and three months after the injection. Results: The best corrected visual acuity, BCVA, whose mean values at baseline were 0.42 logMAR, improved significantly post dexamethasone injection, with mean values of 0.20 logMAR at one month and 0.24 logMAR at three months. The mean central retinal thickness, CRT, was 463 µm at baseline increasing to 297 µm at one month, and 315 µm at three months. Mean retinal sensitivity (MRS) was 12.31 dB at baseline. In line with other parameters, MRS also showed significant improvement at one month after slow-release dexamethasone treatment, with a mean value of 15.35 Db and the improvement was sustained at three months after injection, with a mean value of 14.71 dB. Fixation stability was assessed using the area of the third BCEA ellipse. At baseline, patients had an ellipse area of 53.68 degrees. At one month after injection, patients showed an improvement, with a mean ellipse area of 5.23 degrees, which was maintained at three months, with a mean ellipse area of 4.13 degrees. Conclusions: The dexamethasone implant of 0.7 mg met the efficacy endpoint for improvement in MRS, BCVA, CRT and fixation stability. Full article
(This article belongs to the Special Issue Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition)
►▼ Show Figures

Figure 1

11 pages, 1603 KiB  
Review
Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development
by Etelka Pöstyéni, Róbert Gábriel and Andrea Kovács-Valasek
Pharmaceutics 2024, 16(10), 1320; https://doi.org/10.3390/pharmaceutics16101320 - 11 Oct 2024
Viewed by 1363
Abstract
Owing to its promiscuous roles, poly (ADP-ribose) polymerase-1 (PARP-1) is involved in various neurological disorders including several retinal pathologies. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus affecting the retina. In the present review, we highlight the importance of [...] Read more.
Owing to its promiscuous roles, poly (ADP-ribose) polymerase-1 (PARP-1) is involved in various neurological disorders including several retinal pathologies. Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus affecting the retina. In the present review, we highlight the importance of PARP-1 participation in pathophysiology of DR and discuss promising potential inhibitors for treatment. A high glucose level enhances PARP-1 expression; PARP inhibitors have gained attention due to their potential therapeutic effects in DR. They target different checkpoints (blocking nuclear transcription factor (NF-κB) activation; oxidative stress protection, influence on vascular endothelial growth factor (VEGF) expression, impacting neovascularization). Nowadays, there are several improved clinical PARP-1 inhibitors with different allosteric effects. Combining PARP-1 inhibitors with other compounds is another promising option in DR treatments. Besides pharmacological inhibition, genetic disruption of the PARP-1 gene is another approach in PARP-1-initiated therapies. In terms of future treatments, the limitations of single-target approaches shift the focus onto combined therapies. We emphasize the importance of multi-targeted therapies, which could be effective not only in DR, but also in other ischemic conditions. Full article
(This article belongs to the Special Issue Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition)
►▼ Show Figures

Figure 1

13 pages, 2357 KiB  
Review
Efficacy and Safety of Fluocinolone Acetonide Implant in Diabetic Macular Edema: Practical Guidelines from Reference Center
by Lucas Sejournet, Thibaud Mathis, Victor Vermot-Desroches, Rita Serra, Ines Fenniri, Philippe Denis and Laurent Kodjikian
Pharmaceutics 2024, 16(9), 1183; https://doi.org/10.3390/pharmaceutics16091183 - 7 Sep 2024
Cited by 1 | Viewed by 1234
Abstract
Diabetic macular edema (DME) is a common complication of diabetic retinopathy. Treatment with intravitreal injections is effective in most cases but is associated with a high therapeutic burden for patients. This implies the need for long-term treatments, such as the fluocinolone acetonide (FAc) [...] Read more.
Diabetic macular edema (DME) is a common complication of diabetic retinopathy. Treatment with intravitreal injections is effective in most cases but is associated with a high therapeutic burden for patients. This implies the need for long-term treatments, such as the fluocinolone acetonide (FAc) implant. A review of basic science, pharmacology, and clinical data was conducted to provide a state-of-the-art view of the FAc implant in 2024. Although generally well tolerated, the FAc implant has been associated with ocular hypertension and cataract, and caution should be advised to the patients in this regard. By synthesizing information across these domains, a comprehensive evaluation can be attained, facilitating informed decision-making regarding the use of the FAc implant in the management of DME. The main objective of this review is to provide clinicians with guidelines on how to introduce and use the FAc implant in a patient with DME. Full article
(This article belongs to the Special Issue Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop